TABLE 1.
Summary of the clinical characteristics of CADM1 in malignant tumors.
| Cancer type | Cases | Expression | Clinical characteristics | PMID |
| Ovarian cancer | 180 | Down | Histological grade, FIGO Stage | 33663040 |
| Lymph node metastasis | ||||
| Cervical cancer | 131 | Down | Histological diagnosis | 31067838 |
| Malignant melanoma | 95 | Down | Overall survival (OS), progression-free survivor | 3091107 |
| Nasopharyngeal carcinoma | 20 | Down | Tumor progression | 29070520 |
| Osteosarcoma | 92 | Down | Overall survival, poor prognosis (PFS) | 30013657 |
| Pancreatic cancer | 20 | Down | Differentiation, lymphatic invasion, TNM stage | 28904340 |
| Non-small cell lung cancer | 40 | Down | Poor overall survival | 33325094 |
| Colorectal cancer | 54 | Down | Dukes’ stage, PT (T1, T2, T3, T4) | 20340131 |
| Gastric cancer | 120 | Down | OS, PFS, TNM stage, differentiation | 31389606 |
| Hepatocellular carcinoma | 90 | Down | T stage, advanced TNM stage, OS | 31118799 |
| 82 | Down | Recurrence after liver transplantation | 21271221 | |
| Breast cancer | 128 | Down | OS, TNM stage, lymph node (LN) metastasis | 31579252 |
| Brain metastasis risk | ||||
| Neuroblastoma | 28 | Down | Disease-free survival, recurrence | 27899382 |
| Glioblastoma | 30 | Down | Median survival, cancer progression | 29921422 |
| Bladder cancer | 84 | Down | Tumor recurrence/size/grade, TNM stage | 30719104 |
| Cutaneous squamous cell carcinoma | 87 | Down | Tumor metastasis, invasive depth | 23812766 |
| Histological grade, OS | ||||
| Clear cell renal cell carcinoma | 64 | Down | AJCC stage, OS | 25031695 |
| Gallbladder cancer | 37 | Down | LN metastasis | 24445397 |
| Kaposi’s sarcoma | / | Up | / | 29698475 |
| Adult T-cell leukemia/lymphoma | 71 | Up | Disease progression | 31642546 |
| Prognostic conversion risk | ||||
| Small cell lung cancer | 28 | Up | Pathological stage | 33298314 |
| Merkel cell carcinoma | / | Up | 33419290 | |
| Mycosis fungoides | / | Up | 33419291 | |
| Sezary syndrome | / | Up | 33419292 |